Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (27785)	2/3/1999 1:39:00 PM
From: Alper H.YUKSEL	Read Replies (3) \| Respond to of 32384

Jesse Eisinger about short covering in Biotech. Ligand not mentioned though. thestreet.com

To: Henry Niman who wrote (27785)	2/4/1999 12:25:00 AM
From: carl w. trygstad	Read Replies (6) \| Respond to of 32384

Disclaimer: I am a physician who works with FDA issues daily, and who owns a few shares of LGND stock. Henry, thank you for your scientific perspective. I can not comment on your financial skills, and recommend all who read this to do their own DD. Your posts seem valid to me from the scientific point and I appreciate your historical perspective. Please continue your breath of truth. A number of months ago it occurred to me that the topical retinoids on the market were indicated for actinic keratosis (very effective) and wrinkles (no experience). Panretin should work well for both and for cutaneous squamous cell carcinoma. The next time my dermatologist wants to remove a basal cell carcinoma from my face I am going to ask to try Panretin first. I wonder how may other physicians will reach the same conclusion. While this is off label and can not be recommended by LGND,until there is published literature, a licensed physician may legally do this as of today. Lastly, my sincere thanks to all those present and past employees of LGND who helped to develop this drug which to me is "proof of concept" in industry terms.